Status: Recruiting

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis

Participants needed: 24

Trial details

Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Cabaletta BioUpdated: Oct 9, 2026Locations: 17

Eligibility criteria

Age ≥18 and ≤70 years of age [+2]

Contraindication to leukapheresis [+6]

Status: Recruiting

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Participants needed: 28

Trial details

Phase: Phase 1, Phase 2Age: 12-65Biological sex: AllType: InterventionalSponsor: Cabaletta BioUpdated: Oct 6, 2026Locations: 23

Eligibility criteria

Age ≥18 and ≤65 (Adults) or Age ≥12 to <18 years (Adolescents) [+4]

Contraindication to leukapheresis [+7]

Status: Recruiting

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Participants needed: 74

Trial details

Phase: Phase 2, Phase 3Age: 6-75Biological sex: AllType: InterventionalSponsor: Cabaletta BioUpdated: Sep 17, 2026Locations: 35

Eligibility criteria

Age ≥18 and ≤75 [+4]

Contraindication to leukapheresis [+18]

Status: Recruiting

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis

Participants needed: 37

Trial details

Phase: Phase 2, Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Cabaletta BioUpdated: Aug 17, 2026Locations: 10

Eligibility criteria

Age ≥18 and ≤75 [+3]

Contraindication to leukapheresis [+7]

Status: Recruiting

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris

Participants needed: 40

Trial details

Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Cabaletta BioUpdated: May 29, 2026Locations: 13

Eligibility criteria

Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti-... [+8]

Active cutaneous lesions associated with PV that indicates mucocutaneous rather... [+9]

Clinical trials

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)